TCR-engineered CD4+ T cells carrying an HLA-DP4-restricted TCR for the cancer-testis antigen MAGE-A3 demonstrated safety and efficacy in inducing objective tumor regression across multiple cancer types, validating the potential of modified MAGE-A3-specific CD4+ T cells [167]. This evidence concerns the gene MAGEA3 and cancer.